

Prequalification Unit Inspection Services
WHO PUBLIC INSPECTION REPORT
WHOPIR

Desk Assessment of Active Pharmaceutical Ingredient (API) Manufacturer

Part 1		General information
Company information		
Name of Manufacturer		Shaanxi Hanjiang Pharmaceutical Group Co., Ltd.
Corporate address of manufacturer		No.3, Lianhua Road, Hanzhong Hi-tech Industries Development Zone, Hanzhong City, Shaanxi Province, China.
Inspected site		
Name & address of manufacturing site		No.3, Lianhua Road, Hanzhong Hi-tech Industries Development Zone, Hanzhong City, Shaanxi Province, China.
Synthetic Unit/Block/Workshop		<ul style="list-style-type: none"> • Workshop 305, Area B, Production line of intermediate of Bedaquiline fumarate. • Workshop 301, General production Area and Clean area II (Crystallization room, Centrifugation room, drying room, Delumping room, Milling room, Homogenization room, Packaging room).
Manufacturing license number		License Code: Shaan 20160117 valid up to 23/06/2030
Desk assessment details		
Start and end dates of review		29/11/2025 – 4/12/2025
Inspection record number		INSP-API-2024-0034
APIs covered by this desk assessment		WHOAPI-511 Bedaquiline fumarate (Pending - under assessment)
List of documents submitted		<ol style="list-style-type: none"> a. list of all regulatory inspections performed in the last 3 years and their outcomes. b. The full inspection reports, including deficiency letters, for inspections performed by a competent stringent regulatory authority in the past three years with a certified translated copy where this is not in English. c. Proof of CAPA implementation and final decision by the competent stringent regulatory authority. d. A copy of the manufacturing authorization and GMP certificate granted by the local national authority. e. The list of all the products including API manufactured onsite.

	<p>f. The most recent product quality review (PQR) of the concerned products.</p> <p>g. The list of any recalls in the past three years related to any product manufactured on site with quality defects.</p> <p>h. A confirmation by the senior quality assurance representative that a full self-inspection or external audit dedicated to the product has been performed and all matters dealt with.</p> <p>i. Master batch manufacturing and packaging records of the WHO product of interest.</p> <p>j. Copy of any warning letter, or equivalent regulatory action, issued by any authority to which the site provides or has applied to provide the product.</p> <p>k. Description of any recent or foreseen out-of-stock situations.</p> <p>l. A list of notifications of upcoming inspections by competent national regulatory authorities in the next 6 months.</p> <p>m. Table to specify which parts of the manufacturing process for the concerned product were covered by the inspection of the competent SRA authorities performed in the last 3 years.</p>										
Any documents missing?	Not applicable										
Part 2	Summary of SRA/WLA inspection evidence considered										
<i>United States Food and Drug Administration (USFDA)</i>	<table border="1"> <tr> <td>Dates of inspection:</td><td>18/09/2023 – 21/09/2023</td></tr> <tr> <td>Type of inspection:</td><td>pre-announced surveillance inspection of an animal drug API manufacturer, conducted under eNSpect Operation ID # 252708</td></tr> <tr> <td>Block/Unit/Workshop:</td><td> <ul style="list-style-type: none"> • Workshop 305, Area B • Workshop 301, General production Area and Clean area II </td></tr> <tr> <td>APIs covered:</td><td>Oxfendazole, Fenbendazole, and Mebendazole.</td></tr> <tr> <td>Physical areas inspected:</td><td>The FDA inspection covered all systems including Quality, Production, Facilities & Equipment, Materials, Packaging & Labeling and the Laboratory System.</td></tr> </table>	Dates of inspection:	18/09/2023 – 21/09/2023	Type of inspection:	pre-announced surveillance inspection of an animal drug API manufacturer, conducted under eNSpect Operation ID # 252708	Block/Unit/Workshop:	<ul style="list-style-type: none"> • Workshop 305, Area B • Workshop 301, General production Area and Clean area II 	APIs covered:	Oxfendazole, Fenbendazole, and Mebendazole.	Physical areas inspected:	The FDA inspection covered all systems including Quality, Production, Facilities & Equipment, Materials, Packaging & Labeling and the Laboratory System.
Dates of inspection:	18/09/2023 – 21/09/2023										
Type of inspection:	pre-announced surveillance inspection of an animal drug API manufacturer, conducted under eNSpect Operation ID # 252708										
Block/Unit/Workshop:	<ul style="list-style-type: none"> • Workshop 305, Area B • Workshop 301, General production Area and Clean area II 										
APIs covered:	Oxfendazole, Fenbendazole, and Mebendazole.										
Physical areas inspected:	The FDA inspection covered all systems including Quality, Production, Facilities & Equipment, Materials, Packaging & Labeling and the Laboratory System.										

Part 3	Summary of the last WHO inspection
Date and conclusion of most recent WHO inspection	The site was not subject to an onsite inspection by WHO in the last 5 years.
Abbreviations	Meaning
BMR	Batch manufacturing record
BPR	Batch production record
CAPA	Corrective and preventive action
CC	Change control
GMP	Good manufacturing practices
NC	Non conformity
NRA	National regulatory agency
PQR	Product quality review
PQS	Pharmaceutical quality system
QA	Quality assurance
QC	Quality control
QCL	Quality control laboratory
QMS	Quality management system
QRM	Quality risk management
RA	Risk assessment
RCA	Root cause analysis
SOP	Standard operating procedure

Part 4	Summary of the assessment of supporting documentation
---------------	--

a) Manufacturing authorization and GMP certificate granted by the local authority:

License issued from Shaanxi Medical Products Admin, code of license: Shaan 20160117 (AhChDh). Issued on 05/11/2025 and Valid up to 23/06/2030.

Certificate of GMP from Shaanxi Medical Products Admin No: 073 of 2025 issued on 05/11/2025.

b) Site master file (SMF):

A detailed SMF was submitted and found acceptable.

c) List of all the APIs or other products (intermediates, dosage forms) manufactured on-site:
the list was provided and reviewed. No issues of concerns were found.

d) List of all regulatory inspections performed in the last 3 years and their outcomes:

No.	Authority	Date	Product	Outcome
1	U.S. FDA	18/09/2023 – 21/09/2023	Oxfendazole, Fenbendazole, and Mebendazole	Accepted
2	Japan PMDA	Sep. 26, 2024	Alendronate Sodium Hydrate	Accepted
3	Japan PMDA	Feb. 21, 2025	Mebendazole	Accepted

e) Most recent product quality review(s) (PQR)(s) of the concerned WHO API(s):

Product Quality Review for Bedaquiline fumarate covered the whole year of 2024. Generally, the PQR was acceptable.

f) Batch manufacturing and packaging record(s), including the analytical part, for the most recently released batch of relevant API(s):

Batch manufacturing and packaging record(s), including the analytical part of the last commercial batches of Bedaquiline fumarate was submitted. These were generally found acceptable.

g) Master batch manufacturing and packaging record(s) of the API(s) of interest:

Master batch manufacturing and packaging record(s) of Bedaquiline fumarate was submitted. These were generally found acceptable.

h) Recalls in the past three years related to APIs with quality defects:

The company provided a statement confirming that no recalls have taken place for the last three years.

i) Confirmation by the senior quality assurance representative that a full self-inspection or external audit dedicated to the API(s) has been performed and all matters dealt with:

A letter was submitted stating that self-inspections and also external inspections were conducted and CAPAs were implemented to ensure the status of compliance is maintained for all quality systems.

j) copy of any warning letter, or equivalent regulatory action, issued by any authority for their market, to which the site provides or has applied to provide the API(s):

The company confirmed that no warning letters have been issued by any regulatory authorities against the site until the application for desk assessment was submitted.

k) Out-of-stock situations:

The company declared that no out-of-stock situation is foreseen for WHO PQ products.

l) Additional documents submitted:

Not applicable.

Part 5	Conclusion – Desk assessment outcome
Based on the previous <i>United States Food and Drug Administration (USFDA)</i> inspection and on the GMP evidence received and reviewed, it is considered that a desk assessment is acceptable in lieu of a WHO onsite inspection. The site Shaanxi Hanjiang Pharmaceutical Group Co., Ltd located at No.3, Lianhua Road, Hanzhong Hi-tech Industries Development Zone, Hanzhong City, Shaanxi Province, China is considered to be operating at an acceptable level of compliance with WHO GMP guidelines.	

This WHOPIR will remain valid for 3 years, provided that the outcome of any inspection conducted during this period is positive.

Part 6	List of guidelines referenced in this inspection report
1.	WHO good manufacturing practices for pharmaceutical products: main principles. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-eighth Report Geneva, World Health Organization, 2014 (WHO Technical Report Series, No. 986), Annex 2. Short name: WHO TRS No. 986, Annex 2 https://www.who.int/publications/m/item/trs986-annex2
2.	WHO good manufacturing practices for active pharmaceutical ingredients. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth Report. Geneva, World Health Organization, 2010 (WHO Technical Report Series, No. 957), Annex 2. Short name: WHO TRS No. 957, Annex 2 https://www.who.int/publications/m/item/annex-2-trs-957
3.	WHO guidance on good practices for desk assessment of compliance with good manufacturing practices, good laboratory practices and good clinical practices for medical products regulatory decisions. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-second Report. Geneva, World Health Organization, 2018 (WHO Technical Report Series, No. 1010), Annex 9. Short name: WHO TRS 1010, Annex 9 https://www.who.int/publications/m/item/trs1010-annex9
4.	WHO Good Manufacturing Practices: water for pharmaceutical use. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-fifth Report. Geneva, World Health Organization, 2021 (WHO Technical Report Series, No. 1033), Annex 3. Short name: WHO TRS No. 1033, Annex 3 https://www.who.int/publications/m/item/annex-3-trs-1033
5.	WHO guidelines for sampling of pharmaceutical products and related materials. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-ninth Report. Geneva, World Health Organization, 2005 (WHO Technical Report Series, No. 929), Annex 4. Short name: WHO TRS No. 929, Annex 4 https://www.who.int/publications/m/item/annex-4-trs-929
6.	WHO good practices for pharmaceutical quality control laboratories. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-seventh Report. Geneva, World Health Organization, 2024 (WHO Technical Report Series, No. 1052), Annex 4. Short name: WHO TRS No. 1052, Annex 4 https://www.who.int/publications/i/item/9789240091030
7.	WHO Good Practices for Pharmaceutical Products Containing Hazardous Substances. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fourth Report. Geneva, World Health Organization, 2010 (WHO Technical Report Series, No. 957), Annex 3. Short name: WHO TRS No. 957, Annex 3 https://www.who.int/publications/m/item/trs957-annex3

8. Guidelines on heating, ventilation and air-conditioning systems for non-sterile pharmaceutical products. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-second Report Geneva, World Health Organization, 2018 (WHO Technical Report Series, No. 1010), Annex 8.

Short name: WHO TRS No. 1010, Annex 8

<https://www.who.int/publications/m/item/Annex-8-trs-1010>

9. Guidelines on heating, ventilation and air-conditioning systems for non-sterile pharmaceutical products. Part 2: Interpretation of Guidelines on heating, ventilation and air-conditioning systems for non-sterile pharmaceutical products. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-third Report Geneva, World Health Organization, 2018 (WHO Technical Report Series, No. 1019), Annex 2.

Short name: WHO TRS No. 1019, Annex 2

<https://www.who.int/publications/m/item/trs1019-annex2>

10. WHO guidelines on transfer of technology in pharmaceutical manufacturing WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-fifth Report Geneva, World Health Organization, 2022 (WHO Technical Report Series, No. 1044), Annex 4.

Short name: WHO TRS No. 1044, Annex 4

<https://cdn.who.int/media/docs/default-source/medicines/norms-and-standards/guidelines/production/trs1044-annex4-technology-transfer-in-pharmaceutical-manufacturing.pdf>

11. WHO good manufacturing practices for sterile pharmaceutical products. Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-fifth Report Geneva, World Health Organization, 2022 (WHO Technical Report Series, No. 1044), Annex 4.

Short name: WHO TRS No. 1044, Annex 2

<https://www.who.int/publications/m/item/trs1044-annex2>

12. General guidelines for the establishment maintenance and distribution of chemical reference substances. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-first Report Geneva, World Health Organization 2007 (WHO Technical Report Series, No.943) Annex 3. **Short name: WHO TRS No. 943, Annex 3**

<https://www.who.int/publications/m/item/trs943-annex3>

13. WHO good practices for pharmaceutical microbiology laboratories. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth Report Geneva, World Health Organization, 2011 (WHO Technical Report Series, No. 961), Annex 2.

Short name: WHO TRS No. 961, Annex 2

<https://www.who.int/publications/m/item/trs961-annex2>

14. WHO guidelines on quality risk management. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-seventh Report Geneva, World Health Organization, 2013 (WHO Technical Report Series, No. 981), Annex 2.

Short name: WHO TRS No. 981, Annex 2

<https://www.who.int/publications/m/item/trs981-annex2>

15. WHO guidelines on variation to a prequalified product. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-seventh Report Geneva, World Health Organization, 2013 (WHO Technical Report Series, No. 981), Annex 3.

Short name: WHO TRS No. 981, Annex 3

<https://www.who.int/publications/m/item/annex-3-trs-981>

16. WHO guidelines for drafting a site master file. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth Report Geneva, World Health Organization, 2011 (WHO Technical Report Series, No. 961), Annex 14.

Short name: WHO TRS No. 961, Annex 14

<https://www.who.int/publications/m/item/tr961-annex14>

17. Good Manufacturing Practices: Guidelines on validation. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-third Report Geneva, World Health Organization, 2019 (WHO Technical Report Series, No. 1019), Annex 3.

Short name: WHO TRS No. 1019, Annex 3

<https://www.who.int/publications/m/item/trs1019-annex3>

18. WHO General guidance on hold-time studies WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-ninth Report Geneva, World Health Organization, 2015 (WHO Technical Report Series, No. 992), Annex 4.

Short name: WHO TRS No. 992, Annex 4

<https://www.who.int/publications/m/item/trs992-annex4>

19. Model guidance for the storage and transport of time-and temperature-sensitive pharmaceutical products. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth Report Geneva, World Health Organization, 2011 (WHO Technical Report Series, No. 961), Annex 9.

Short name: WHO TRS No. 961, Annex 9

<https://www.who.int/publications/m/item/trs961-annex9-modelguidanceforstoragetransport>

20. WHO Technical supplements to Model Guidance for storage and transport of time – and temperature – sensitive pharmaceutical products. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-ninth Report Geneva, World Health Organization, 2015 (WHO Technical Report Series, No. 992), Annex 5.

Short name: WHO TRS No. 992, Annex 5

<https://www.who.int/publications/m/item/trs992-annex5>

21. WHO Recommendations for quality requirements when plant – derived artemisinin is used as a starting material in the production of antimalarial active pharmaceutical ingredients. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-ninth Report Geneva, World Health Organization, 2015 (WHO Technical Report Series, No. 992), Annex 6.

Short name: WHO TRS No. 992, Annex 6

<https://www.who.int/publications/m/item/trs-992-annex-6>

22. Guideline on data integrity. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-fifth Report Geneva, World Health Organization, 2021 (WHO Technical Report Series, No. 1033), Annex 4.

Short name: WHO TRS No. 1033, Annex 4

<https://www.who.int/publications/m/item/annex-4-trs-1033>

23. WHO general guidance on variations to multisource pharmaceutical products. *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fiftieth Report* Geneva, World Health Organization, 2016 (WHO Technical Report Series, No. 996), Annex 10.

Short name: WHO TRS No. 996, Annex 10

<https://www.who.int/publications/m/item/trs966-annex10>

24. Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-second Report Geneva, World Health Organization, 2018 (WHO Technical Report Series, No. 1010), Annex 10.

Short name: WHO TRS No. 1010, Annex 10

<https://www.who.int/publications/m/item/trs1010-annex10>

25. Points to consider when including Health-Based Exposure Limits in cleaning validation. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-fifth Report Geneva, World Health Organization, 2021 (WHO Technical Report Series, No. 1033), Annex 2.

Short name: WHO TRS No. 1033, Annex 2

<https://www.who.int/publications/m/item/annex-2-trs-1033>

26. Points to consider for manufacturers and inspectors: environmental aspects of manufacturing for the prevention of antimicrobial resistance. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-fourth Report Geneva, World Health Organization, 2020 (WHO Technical Report Series, No. 1025), Annex 6.

Short name: WHO TRS No. 1025, Annex 6

<https://www.who.int/publications/m/item/trs-1025-annex-6>

27. Production of water for injection by means other than distillation. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-fourth Report. Geneva, World Health Organization, 2020 (WHO Technical Report Series, No. 1025), Annex 3.

Short name: WHO TRS No. 1025, Annex 3

<https://www.who.int/publications/m/item/trs-1025-annex-3-water-for-injection>

28. Good chromatography practice. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fifty-fourth Report. Geneva, World Health Organization, 2020 (WHO Technical Report Series, No. 1025), Annex 4.

Short name: WHO TRS No. 1025, Annex 4

<https://www.who.int/publications/m/item/trs1025-annex4>

29. Good trade and distribution practices for pharmaceutical starting materials. *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Fiftieth Report* Geneva, World Health Organization, 2016 (WHO Technical Report Series, No. 996), Annex 6.

Short name: WHO TRS No. 996, Annex 6

<https://www.who.int/publications/m/item/annex-6-trs-996>

30. WHO guidelines for preparing a laboratory information file. *WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-fifth Report* Geneva, World Health Organization, 2011 (WHO Technical Report Series, No. 961), Annex 13.

Short name: WHO TRS No. 961, Annex 13

<https://www.who.int/publications/m/item/trs961-annex13>

31. WHO good manufacturing practices for excipients used in pharmaceutical products. WHO Expert Committee on Specifications for Pharmaceutical Preparations. *Fifty-seventh Report*. Geneva, World Health Organization, 2024 (WHO Technical Report Series, No. 1052), Annex 1.

Short name: WHO TRS No. 1052, Annex 1

<https://www.who.int/publications/i/item/9789240091030>